![ORR高达100%!这个命途坎坷的CAR-T疗法终于迎来了天亮……](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![新冠KP.2变异株已在我国发现,泰中定@纳入医保,更低负担更高可及!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
01
阿新冠病毒威胁未减
泰中定®成防护新选择
02
从临床数据看疗效:
泰中定®在多个维度超越Paxlovid
![新冠KP.2变异株已在我国发现,泰中定@纳入医保,更低负担更高可及!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
03
泰中定®:
实惠又有效的新馆治疗选择
参考来源:
-
Hongzhou Lu, George Zhang, John Mao, et al. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial. eClinicalMedicine. 2024;71:102582.
-
https://www.who.int/zh/news/item/10-11-2023-who-updates-guidelines-on-treatments-for-covid-19
-
http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/460b0e7b19bd42f3bba00c1efb9b6811.pdf
![新冠KP.2变异株已在我国发现,泰中定@纳入医保,更低负担更高可及!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![新冠KP.2变异株已在我国发现,泰中定@纳入医保,更低负担更高可及!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
中国新冠药登上《柳叶刀》子刊
![新冠KP.2变异株已在我国发现,泰中定@纳入医保,更低负担更高可及!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
广生堂的创新药转型里程碑:第一款创新药产品获批上市,仍聚焦抗病毒领域……
![新冠KP.2变异株已在我国发现,泰中定@纳入医保,更低负担更高可及!](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
广生堂广谱抗新冠病毒口服3CL抑制剂GST-HG171获批进入临床试验
本篇文章来源于微信公众号: 药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权